Replies to post #205237 on Biotech Values

[ghmm]

ADVM:

I found the Annapuma assets more interesting then the Avalanche (I am long the stock) though I am obviously disappointed with the delay. All things considered its probably best that Salzman is now the CEO. They still have the partnership with Regeneron and claim their biofactory platform can be leveraged for many eye disease though I am not giving it and the earlier program with Editas much value at this point. They are well below cash and I was hoping some early human data would come while the balance sheet is still reasonable.

Here is a recent presentation from the Ophthalmology Innovation Summit
https://www.sec.gov/Archives/edgar/data/1501756/000119312516737669/d230538dex991.htm